Biohit's Non-Invasive Diagnostic Tools For Assessment Of Function And Structure Of The Stomach Mucosa

Medical News Today -- Risks for gastric cancer or peptic ulcer diseases are low in subjects with healthy stomach mucosa but are remarkably high in those with "diseased" stomach mucosa: i.e., in those with H pylori gastritis or atrophic gastritis. Therefore, the differentiation between patients with healthy (no H pylori, gastritis, or atrophic gastritis) and diseased gastric mucosa is clinically relevant. Serum levels of pepsinogen have been used for decades to diagnose atrophic corpus gastritis non-invasively. Recently, a European biomarker examination, GastroPanel (Biohit Plc, Helsinki, Finland), has been validated in which, in addition to Pg assays, the serum or plasma levels of gastrin-17 and H pylori antibodies of both IgG and IgA class are measured from the same sample using an ELISA technique.